Type II Endometrial Adenocarcinoma — Trials

Type II Endometrial Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

59 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 17
Recruiting: 9
Ph III recruiting: 2
Growth YoY: —
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (6)

clinicaltrialsPublishedShowing 51–59 of 59 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01642082	Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer	completed	Phase 2	28	Gynecologic Oncology GroupNETWORK	1	Mar 13, 2018	clinicaltrials
NCT01210222	Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer	completed	Phase 2	35	Gynecologic Oncology GroupNETWORK	1	Feb 23, 2018	clinicaltrials